Biofrontera Inc.
BFRI Healthcare Drug Manufacturers Specialty & Generic
Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.9%, EPS grew 91.2%, free cash flow grew 45.6% and total debt rose 6.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow BFRI
Biofrontera Inc. (BFRI) EV/Sales
As of 16 October 2026, Biofrontera Inc. (BFRI) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −0.6× (September 2022) to 5.7× (December 2021); the current reading is higher than 72% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.1× | (14.70%) |
| FY2024 | 0.1× | (44.36%) |
| FY2023 | 0.2× | — |
| FY2022 | −0.3× | — |
| FY2021 | 1.7× | (6.27%) |
| FY2020 | 1.8× | 0.00% |
| FY2019 | 1.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.3× | 43.77% |
| Mar 2026 | 0.2× | 83.74% |
| Dec 2025 | 0.1× | (68.19%) |
| Sep 2025 | 0.3× | 214.41% |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPC Universe Pharmaceuticals INC compare | −0.2× |
| SNOA Sonoma Pharmaceuticals, Inc. compare | 0.0× |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| BGXXQ Bright Green Corporation compare | n/m |
| BFRI Biofrontera Inc. | 0.2× |
| AYTU Aytu BioPharma, Inc. compare | 0.3× |
| INM InMed Pharmaceuticals Inc. compare | 0.6× |
| TXMD TherapeuticsMD, Inc. compare | 85.1× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)